Foghorn Therapeutics Inc.
NASDAQFoghorn Therapeutics enters the back half of May with momentum firmly against it — a Q1 revenue miss triggered a 14.6% weekly decline, and the stock now trades at $3.79, down more than 20% over the past month. The Q1 print, released May 7, was the root of the damage. EPS came in at -$0.29, broadly in line, but revenue of $3.3 million badly missed the $7.4 million estimate. The…
Snapshot as of 16 May 2026
Foghorn Therapeutics enters the back half of May with momentum firmly against it — a Q1 revenue miss triggered a 14.6% weekly decline, and the stock now trades at $3.79, down more than 20% over the past month. The Q1…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for FHTX — free to start on ORTEX.
Sign up for free →Open FHTX on ORTEX